Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 445 to 448 of 448 entries
Sorted by: Best Match Show Resources per page
Can we deliver randomized trials of focal therapy in prostate cancer?.

Nature reviews. Clinical oncology

Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M.
PMID: 24751803
Nat Rev Clin Oncol. 2014 Aug;11(8):482-91. doi: 10.1038/nrclinonc.2014.44. Epub 2014 Apr 22.

Tissue-preserving focal therapies, such as brachytherapy, cryotherapy, high-intensity focused ultrasound and photodynamic therapy, aim to target individual cancer lesions rather than the whole prostate. These treatments have emerged as potential interventions for localized prostate cancer to reduce treatment-related adverse-effects...

Cite
Ahmed HU, Berge V, Bottomley D, et al. Can we deliver randomized trials of focal therapy in prostate cancer?. Nat Rev Clin Oncol. 2014;11(8):482-91doi: 10.1038/nrclinonc.2014.44.
Ahmed, H. U., Berge, V., Bottomley, D., Cross, W., Heer, R., Kaplan, R., Leslie, T., Parker, C., Relton, C., Stephens, R., Sydes, M. R., Turnbull, L., van der Meulen, J., Vickers, A., Wilt, T., Emberton, M. (2014). Can we deliver randomized trials of focal therapy in prostate cancer?. Nature reviews. Clinical oncology, 11(8), 482-91. https://doi.org/10.1038/nrclinonc.2014.44
Ahmed, Hashim U, et al. "Can we deliver randomized trials of focal therapy in prostate cancer?." Nature reviews. Clinical oncology vol. 11,8 (2014): 482-91. doi: https://doi.org/10.1038/nrclinonc.2014.44
Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M. Can we deliver randomized trials of focal therapy in prostate cancer?. Nat Rev Clin Oncol. 2014 Aug;11(8):482-91. doi: 10.1038/nrclinonc.2014.44. Epub 2014 Apr 22. PMID: 24751803.
Copy Download .nbib Format: NLM
A commentary on "Moderate and severe exacerbations have a significant impact on health related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis" (Int J Surg 2020; 78:28-35).

International journal of surgery (London, England)

Li XM, Wang HX, Wang HY.
PMID: 33940198
Int J Surg. 2021 Jun;90:105961. doi: 10.1016/j.ijsu.2021.105961. Epub 2021 May 01.

No abstract available.

Cite
Li XM, Wang HX, Wang HY. A commentary on "Moderate and severe exacerbations have a significant impact on health related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis" (Int J Surg 2020; 78:28-35). Int J Surg. 2021;90:105961doi: 10.1016/j.ijsu.2021.105961.
Li, X. M., Wang, H. X., & Wang, H. Y. (2021). A commentary on "Moderate and severe exacerbations have a significant impact on health related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis" (Int J Surg 2020; 78:28-35). International journal of surgery (London, England), 90105961. https://doi.org/10.1016/j.ijsu.2021.105961
Li, Xiao-Ming, et al. "A commentary on "Moderate and severe exacerbations have a significant impact on health related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis" (Int J Surg 2020; 78:28-35)." International journal of surgery (London, England) vol. 90 (2021): 105961. doi: https://doi.org/10.1016/j.ijsu.2021.105961
Li XM, Wang HX, Wang HY. A commentary on "Moderate and severe exacerbations have a significant impact on health related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis" (Int J Surg 2020; 78:28-35). Int J Surg. 2021 Jun;90:105961. doi: 10.1016/j.ijsu.2021.105961. Epub 2021 May 01. PMID: 33940198.
Copy Download .nbib Format: NLM
In for the long-haul? Seropositivity and sequelae 1 year post COVID-19.

BMC medicine

Deuel JW, Schlagenhauf P.
PMID: 34517856
BMC Med. 2021 Sep 14;19(1):200. doi: 10.1186/s12916-021-02084-4.

No abstract available.

Cite
Deuel JW, Schlagenhauf P. In for the long-haul? Seropositivity and sequelae 1 year post COVID-19. BMC Med. 2021;19(1):200doi: 10.1186/s12916-021-02084-4.
Deuel, J. W., & Schlagenhauf, P. (2021). In for the long-haul? Seropositivity and sequelae 1 year post COVID-19. BMC medicine, 19(1), 200. https://doi.org/10.1186/s12916-021-02084-4
Deuel, Jeremy Werner, and Schlagenhauf, Patricia. "In for the long-haul? Seropositivity and sequelae 1 year post COVID-19." BMC medicine vol. 19,1 (2021): 200. doi: https://doi.org/10.1186/s12916-021-02084-4
Deuel JW, Schlagenhauf P. In for the long-haul? Seropositivity and sequelae 1 year post COVID-19. BMC Med. 2021 Sep 14;19(1):200. doi: 10.1186/s12916-021-02084-4. PMID: 34517856; PMCID: PMC8437657.
Copy Download .nbib Format: NLM
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.

Multiple sclerosis (Houndmills, Basingstoke, England)

Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M.
PMID: 33900144
Mult Scler. 2021 Sep;27(10):1543-1555. doi: 10.1177/13524585211010128. Epub 2021 Apr 26.

BACKGROUND: The optimal timing of treatment starts for achieving the best control on the long-term disability accumulation in multiple sclerosis (MS) is still to be defined.OBJECTIVE: The aim of this study was to estimate the optimal time to start...

Cite
Iaffaldano P, Lucisano G, Butzkueven H, et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021;27(10):1543-1555doi: 10.1177/13524585211010128.
Iaffaldano, P., Lucisano, G., Butzkueven, H., Hillert, J., Hyde, R., Koch-Henriksen, N., Magyari, M., Pellegrini, F., Spelman, T., Sørensen, P. S., Vukusic, S., & Trojano, M. (2021). Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple sclerosis (Houndmills, Basingstoke, England), 27(10), 1543-1555. https://doi.org/10.1177/13524585211010128
Iaffaldano, Pietro, et al. "Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 27,10 (2021): 1543-1555. doi: https://doi.org/10.1177/13524585211010128
Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021 Sep;27(10):1543-1555. doi: 10.1177/13524585211010128. Epub 2021 Apr 26. PMID: 33900144.
Copy Download .nbib Format: NLM
Showing 445 to 448 of 448 entries